India's AI and Genomics Leap in Healthcare
Analysis based on 7 articles · First reported Feb 21, 2026 · Last updated Feb 23, 2026
The advancements in AI for medical diagnosis and genomics in India are expected to significantly boost the healthcare and biotechnology sectors. Increased private participation in these areas, encouraged by the Indian government, could lead to new investment opportunities and technological breakthroughs, positively impacting market sentiment for related companies.
Union Minister of State Jitendra Singh announced that Artificial intelligence-developed tools are poised to revolutionize medical diagnosis by eliminating subjectivity and ensuring more precise and specific treatments for patients in India. Speaking at the 'Medllumina 2026: International Multi Specialty Medical Conference', he highlighted how AI-enabled systems can reduce human error in pathology and clinical examinations by analyzing comprehensive patient data. Singh also emphasized India's entry into a new era of genomics and gene therapy, with the India===Department of Biotechnology undertaking large-scale genome sequencing. He cited the successful clinical research in gene therapy for haemophilia and the development of India's first indigenous antibiotic, Nafithromycin, as significant scientific achievements. The Minister noted that personalized prescriptions based on genetic profiling will become the norm, and the government is opening sectors like space, nuclear medicine, and advanced health research to greater private participation to foster innovation and build a 'Viksit Bharat'.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard